Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Return on Equity (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Return on Equity for 5 consecutive years, with 0.13% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Equity rose 21.0% year-over-year to 0.13%, compared with a TTM value of 0.13% through Dec 2025, up 21.0%, and an annual FY2025 reading of 0.14%, up 22.0% over the prior year.
  • Return on Equity was 0.13% for Q4 2025 at Kiniksa Pharmaceuticals International, up from 0.09% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.58% in Q2 2023 and bottomed at 0.83% in Q4 2021.
  • Average Return on Equity over 5 years is 0.02%, with a median of 0.11% recorded in 2024.
  • Peak annual rise in Return on Equity hit 133bps in 2023, while the deepest fall reached -52bps in 2023.
  • Year by year, Return on Equity stood at 0.83% in 2021, then soared by 157bps to 0.47% in 2022, then crashed by -64bps to 0.17% in 2023, then crashed by -147bps to 0.08% in 2024, then surged by 257bps to 0.13% in 2025.
  • Business Quant data shows Return on Equity for KNSA at 0.13% in Q4 2025, 0.09% in Q3 2025, and 0.03% in Q2 2025.